Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.

Participants needed: 446
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Miracogen Inc.Updated: Jan 20, 2026Locations: 1
Eligibility criteria

Willing to sign the informed consent form and follow the requirements specified... [+7]

History of hypersensitivity to any component of the investigational product. [+15]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.

Participants needed: 116
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Miracogen Inc.Updated: Jul 8, 2025Locations: 1
Eligibility criteria

Willing to sign the ICF and follow the requirements specified in the protocol. [+8]

History of 4 or more systemic anti-tumor therapies for the recurrent or metastat... [+24]

Read more
Status: Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.

Participants needed: 290
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Miracogen Inc.Updated: Apr 13, 2023Locations: 1
Eligibility criteria

1. Willing to sign the ICF and follow the requirements specified in the protocol...

1. History of hypersensitivity to any component of MRG002 or history of hypersen...

Read more